Zobrazeno 1 - 10
of 350
pro vyhledávání: '"Simone Ribero"'
Publikováno v:
Frontiers in Medicine, Vol 11 (2024)
Externí odkaz:
https://doaj.org/article/7d26cfef736148cb8d21e50168898a29
Autor:
Giacomo Caldarola, Giulia Raimondi, Tonia Samela, Lorenzo Pinto, Francesca Pampaloni, Michela Valeria Rita Starace, Laura Diluvio, Federica Dall'Oglio, Emanuele Vagnozzi, Maria Beatrice de Felici del Giudice, Riccardo Balestri, Francesca Ambrogio, Giampiero Girolomoni, Silvia Francesca Riva, Francesco Moro, Laura Atzori, Giuseppe Gallo, Simone Ribero, Oriana Simonetti, Stefania Barruscotti, Valeria Boccaletti, Angelo Valerio Marzano, Luca Bianchi, Giuseppe Micali, Bianca Maria Piraccini, Maria Concetta Fargnoli, Damiano Abeni, Ketty Peris
Publikováno v:
Frontiers in Public Health, Vol 12 (2024)
ObjectiveThe prevalence of anxiety and depression in patients diagnosed with Alopecia Areata (AA) is very high and this significant burden of psychological symptoms threatens the Health-Related Quality of Life (HRQoL) of affected patients. Indeed, AA
Externí odkaz:
https://doaj.org/article/b1023e06198e49f985e68a7130b75d06
Autor:
Giusy Schipani, Steven P. Nisticò, Pietro Quaglino, Simone Ribero, Giuseppe Gallo, Vincenzo Maione, Giampiero Girolomoni, Paolo Rosina, Mauro Alaibac, Francesco Messina, Alessandro Gatti, Giuseppe Stinco, Cinzia Buligan, Sara Bassoli, Francesca Farnetani, Alessandro Borghi, Davide Melandri, Riccardo Sirna, Luca Feci, Stefano Simonetti, Luca Stingeni, Annamaria Offidani, Valerio Brisigotti, Anna Campanati, Stefano Calvieri, Giulia Spallone, Elisabetta Botti, Vincenzo Panasiti, Gianluca Pagnanelli, Massimiliano Scalvenzi, Gabriella Fabbrocini, Claudia Costa, Vincenzo Schirripa, Francesco Borgia, Laura Atzori, Elisabetta Scali, Maria Passante, Fabrizio Guarneri, Cataldo Patruno
Publikováno v:
JEADV Clinical Practice, Vol 3, Iss 1, Pp 76-85 (2024)
Abstract Background Primitive location of melanoma could be a relevant prognostic factor. As regards the scalp, some studies indicate a particularly aggressive biological behaviour for this anatomical localisation. Objectives In this multicentric stu
Externí odkaz:
https://doaj.org/article/3268f3c84e894b2f83d099b916a236a1
Autor:
Luigi Gargiulo, Luciano Ibba, Ruggero Cascio Ingurgio, Piergiorgio Malagoli, Fabrizio Amoruso, Anna Balato, Federico Bardazzi, Pina Brianti, Giovanna Brunasso, Martina Burlando, Anna E. Cagni, Marzia Caproni, Carlo G. Carrera, Andrea Carugno, Francesco Caudullo, Aldo Cuccia, Paolo Dapavo, Eugenia V. Di Brizzi, Valentina Dini, Francesca M. Gaiani, Paolo Gisondi, Claudio Guarneri, Claudia Lasagni, Gaetano Licata, Francesco Loconsole, Angelo V. Marzano, Matteo Megna, Santo R. Mercuri, Maria L. Musumeci, Diego Orsini, Simone Ribero, Valentina Ruffo Di Calabria, Francesca Satolli, Davide Strippoli, Massimo Travaglini, Emanuele Trovato, Marina Venturini, Leonardo Zichichi, Mario Valenti, Antonio Costanzo, Alessandra Narcisi
Publikováno v:
Journal of Dermatological Treatment, Vol 35, Iss 1 (2024)
AbstractPurpose Tildrakizumab is a selective inhibitor of IL-23 approved for the treatment of moderate-to-severe plaque psoriasis in two dosages. We conducted a 16-week multicenter retrospective study to compare the effectiveness and safety of tildra
Externí odkaz:
https://doaj.org/article/50011e4f4d42477e96cf16f9d602b59b
Autor:
Gabriele Roccuzzo, Nicole Macagno, Cristina Sarda, Jelena Pisano, Simone Ribero, Paolo Fava, Pietro Quaglino
Publikováno v:
Acta Dermato-Venereologica, Vol 104 (2024)
Abstract is missing (Short communication)
Externí odkaz:
https://doaj.org/article/55a3c5ca707744b4be8760021a12564a
Autor:
Luca Mastorino, Paolo Dapavo, Caterina Cariti, Sara Susca, Niccolò Siliquini, Michela Ortoncelli, Elena Stroppiana, Anna Verrone, Isotta Giunipero di Corteranzo, Francesco Leo, Pietro Quaglino, Simone Ribero
Publikováno v:
Journal of Personalized Medicine, Vol 14, Iss 7, p 718 (2024)
Introduction: the selective IL-17 inhibitor secukinumab has demonstrated efficacy and safety in the treatment of moderate–severe psoriasis in recent years. Objective: evaluate effectiveness and drug survival (DS) of secukinumab in patients with pso
Externí odkaz:
https://doaj.org/article/7cbc7200b2904eaebb71c829230b3b22
Autor:
Gianluca Avallone, Isotta Giunipero di Corteranzo, Rebecca Senetta, Gabriele Roccuzzo, Pietro Quaglino, Simone Ribero
Publikováno v:
Dermatology Practical & Conceptual, Vol 14, Iss 1 (2024)
Externí odkaz:
https://doaj.org/article/57a99a1091d24cc5b65d94cd92466832
Autor:
Martina Merli, Martina Accorinti, Maurizio Romagnuolo, Angelo Marzano, Giovanni Di Zenzo, Francesco Moro, Emiliano Antiga, Roberto Maglie, Emanuele Cozzani, Aurora Parodi, Giulia Gasparini, Pietro Sollena, Clara De Simone, Marzia Caproni, Luigi Pisano, Davide Fattore, Riccardo Balestri, Paolo Sena, Pamela Vezzoli, Miriam Teoli, Marco Ardigò, Camilla Vassallo, Andrea Michelerio, Rosanna Rita Satta, Emi Dika, Barbara Melotti, Simone Ribero, Pietro Quaglino
Publikováno v:
Frontiers in Medicine, Vol 10 (2023)
Cutaneous immune-related adverse events are frequently associated with immune checkpoint inhibitors (ICIs) administration in cancer patients. In fact, these monoclonal antibodies bind the cytotoxic T-lymphocyte antigen-4 and programmed cell death-1/l
Externí odkaz:
https://doaj.org/article/54cab3571bda4d5c925013a4dc3c5c86
Autor:
Elena Pezzolo, Michela Ortoncelli, Silvia Mariel Ferrucci, Mario Bruno Guanti, Donatella Schena, Maddalena Napolitano, Mariateresa Rossi, Caterina Foti, Domenico D’Amico, Giuseppe Fabrizio Amoruso, Pietro Morrone, Simone Ribero, Francesca Barei, Matteo Biagi, Enrico Pascucci, Cataldo Patruno, Piergiacomo Calzavara Pinton, Paolo Romita, Luigi Gargiulo, Alessandra Narcisi, Luigi Naldi
Publikováno v:
Journal of Clinical Medicine, Vol 13, Iss 2, p 553 (2024)
Background: Limited real-world data are available on upadacitinib drug survival in patients with atopic dermatitis (AD). Objectives: To investigate upadacitinib drug survival, and the reasons and predictors of drug discontinuation in AD patients. Met
Externí odkaz:
https://doaj.org/article/705cf9067ad248119e87e80db886fe52
Autor:
Silvia Giordano, Paolo Dapavo, Michela Ortoncelli, Elena Stroppiana, Anna Verrone, Pietro Quaglino, Simone Ribero, Luca Mastorino
Publikováno v:
Journal of Clinical Medicine, Vol 12, Iss 24, p 7503 (2023)
Background: Interleukin 23 (IL-23) inhibitors, such as guselkumab, risankziumab, and tildrakizumab, have proved to be highly effective and safe for psoriasis treatment either in bio-naïve or bio-experienced patients. A substantial proportion of pati
Externí odkaz:
https://doaj.org/article/b92674edf6e641f0baebfbe49505b001